Evaluation of SARS-CoV-2 neutralizing antibodies using a vesicular stomatitis virus possessing SARS-CoV-2 spike protein

Hideki Tani1,2*, Miyuki Kimura1, Long Tan1, Yoshihiro Yoshida1, Tatsuhiko Ozawa3, Hiroyuki Kishi3, Shuetsu Fukushi4, Masayuki Saijo6, Kaori Sano5, Tadaki Suzuki5, Hitoshi Kawasui6, Akitoshi Ueno6, Yuki Miyajima6, Yasutaka Fukui6, Ippei Sakamaki6, Yoshihiro Yamamoto6 and Yoshitomo Morinaga1

Abstract

Background: SARS-CoV-2 is a novel coronavirus that emerged in 2019 and is now classified in the genus Coronavirus with closely related SARS-CoV. SARS-CoV-2 is highly pathogenic in humans and is classified as a biosafety level (BSL)-3 pathogen, which makes manipulating it relatively difficult due to its infectious nature.

Methods: To circumvent the need for BSL-3 laboratories, an alternative assay was developed that avoids live virus and instead uses a recombinant VSV expressing luciferase and possesses the full length or truncated spike proteins of SARS-CoV-2. Furthermore, to measure SARS-CoV-2 neutralizing antibodies under BSL2 conditions, a chemiluminescence reduction neutralization test (CRNT) for SARS-CoV-2 was developed. The neutralization values of the serum samples collected from hospitalized patients with COVID-19 or SARS-CoV-2 PCR-negative donors against the pseudotyped virus infection evaluated by the CRNT were compared with antibody titers determined from an enzyme-linked immunosorbent assay (ELISA) or an immunofluorescence assay (IFA).

Results: The CRNT, which used whole blood collected from hospitalized patients with COVID-19, was also examined. As a result, the inhibition of pseudotyped virus infection was specifically observed in both serum and whole blood and was also correlated with the results of the IFA.

Conclusions: In conclusion, the CRNT for COVID-19 is a convenient assay system that can be performed in a BSL-2 laboratory with high specificity and sensitivity for evaluating the occurrence of neutralizing antibodies against SARS-CoV-2.

Keywords: Pseudotyped virus, VSV, SARS-CoV-2, Neutralization assay, Serum, Whole blood

Background

Recently, the infectious Coronavirus Disease 2019 (COVID-19) emerged and is caused by a newly identified coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1]. Globally, COVID-19 severely impacted health and socio-economic conditions.

Currently, no safe and effective antivirals or other therapies for COVID-19 exist, although some drugs, such as remdesivir, showed limited efficacy for the treatment of patients with COVID-19 [2, 3]. Similar to other diseases, proper treatment requires an accurate diagnosis. Therefore, establishing diagnostics, such as the detection of target viral genes and antibodies, is also required.

The genome structure of SARS-CoV-2 is similar to that of severe acute respiratory syndrome coronavirus SARS-CoV, which is the causative agent for severe acute respiratory syndrome (SARS) that showed high mortality.
and morbidity in the late 2002–to the middle of 2003 outbreak, which mainly occurred in China [4]. The proteins of SARS-CoV-2 consist of two large polyproteins: ORF1a and ORF1ab; four structural proteins: spike (S), envelope (E), membrane (M), and nucleocapsid (N); and eight accessory proteins: ORF3a, ORF3b, ORF6, ORF7a, ORF7b, ORF8a, ORF8b, and ORF9b. S protein is a glycoprotein, which is responsible for binding and penetration of target cells. The S protein is also important for induction of protective humoral and cellular immunity during infection. The S protein is the main target with which the neutralizing antibodies react. Measuring the SARS-CoV-2 neutralizing antibodies is important for proper diagnosis, to study the serological epidemiology and determine infection control of SARS-CoV-2.

The enzyme-linked immunosorbent assay (ELISA), immunofluorescence assay (IFA), and immunochromatography utilize the principle of antigen–antibody reaction and were developed as serodiagnostic methods for SARS-CoV-2 infection. The specificity of these assays is fairly high, but problems are present such as relatively low sensitivity except for ELISA and a high rate of false positives. The neutralization antibody test (NT) for serum using live SARS-CoV-2 is a method in which inhibition of the serum upon viral infection is observed in the presence of neutralizing antibodies against proteins involved in viral binding and penetration in the serum. Generally, the NT is the standard method used to confirm the presence of neutralizing antibodies against SARS-CoV-2. However, this method takes a long time because it depends on the growth of the virus, and it is not a simple measuring system in terms of complicated handling and biosafety for highly pathogenic SARS-CoV-2. Therefore, recently, a pseudotyped virus system based on vesicular stomatitis virus (VSV) or pseudotyped particle systems based on lentivirus or retrovirus were developed for the detection of neutralizing antibodies instead of using infectious and authentic virions of VSV [14, 15].

Methods
Plasmids
The cDNAs of the SARS-CoV-2 spike protein were obtained by chemical synthesis with optimization for the humanized codon (Integrated DNA Technologies, Inc., Coralville, IA). The S cDNA of SARS-CoV-2 was cloned into the pCAGGS expression vector [13]. The resulting plasmid was designated as pCAG-SARS-CoV-2. The plasmid, which contains the S protein gene with a 19 aa truncation at the C-terminus, was constructed using the cDNA of pCAG-SARS-CoV-2. The S proteins with the 19 aa deletion of coronaviruses were previously reported to show increased efficiency regarding incorporation into virions of VSV [14, 15].

Cells
Human (Huh7 and 293 T), monkey (Vero), hamster (BHK and CHO), and mouse (NIH3T3) cell lines were obtained from the American Type Culture Collection (Summit Pharmaceuticals International, Tokyo, Japan). All cell lines were grown in Dulbecco’s modified Eagle’s medium (DMEM; Nacalai Tesque, Inc., Kyoto, Japan) containing 10% heat inactivated fetal bovine serum (FBS).

Generation of pseudotyped VSVs
Pseudotyped VSVs bearing the S protein, the 19 aa-truncated S protein of SARS-CoV-2, or VSV-G were generated as described below. Briefly, 293 T cells were grown to 80% confluence on collagen-coated tissue culture plates and then transfected with each expression vector: pCAG-SARS-CoV-2 S-full, pCAG-SARS-CoV-2 S-t19, and pCAG-VSV-G. After 24 h of incubation, the cells transfected with each plasmid were infected with G-complemented ("G") VSVΔG/Luc ("G-VSVΔG/Luc") [16] at a multiplicity of infection (MOI) of 0.5 per cell. Then, the virus was adsorbed and extensively washed four times with 10% FBS DMEM. After 24 h of incubation, to remove cell debris, the culture supernatants containing pseudotyped VSVs were centrifuged, and then, they stored at −80 °C until ready for use. The pseudotyped VSV bearing SARS-CoV-2 S protein or SARS-CoV-2 truncated S protein are referred to as Sfullpv or St19pv, respectively. The infectivity of Sfullpv, St19pv, or VSVpv to 293 T cells was assessed by measuring the luciferase activity. The value of the relative light unit (RLU) of luciferase was determined using a PicaGene Luminescence Kit (TOYO B-Net Co., LTD, Tokyo, Japan) and GloMax
negative donors and then inoculated with Sfullpv, St19pv, valescent patients with COVID-19 or COVID-19 PCR-treated with serially diluted sera or whole blood of convalescent patients against pseudotyped viruses, Vero cells were inoculated with the human serum or whole blood samples against pseudotyped viruses. Vero cells were incubated with the patient sera used in this study were collected from hospitalized patients (the University of Toyama Hospital) with COVID-19. By using a blood collection tube containing EDTA, blood samples were obtained from 5 hospitalized patients who were admitted to the University of Toyama Hospital, Toyama, Japan. In addition, nineteen serum samples were collected from COVID-19 PCR-negative donors at the University of Toyama Hospital. All of the sera were heat-inactivated at 56 °C for 30 min. The diagnosis of COVID-19 in all patients or donors was assessed using the real-time PCR method with specific primers, which were developed at the National Institute of Infectious Diseases, Japan [17].

Expression and purification of recombinant SARS-CoV-2 trimeric spike protein
SARS-CoV-2 monomeric spike (S) proteins were produced using a mammalian cell protein expression system. The S gene sequence (GenBank: MN908947) was commercially synthesized (Genewiz, Japan). The extracellular region of the S sequence (amino acids 1–1213; MFVF…IKWP) was codon optimized for mammalian cell expression and the polybasic cleavage site was removed (RRAR to A) with stabilizing mutations (K986P and V987P; wild-type numbering) added as described by Amanat et al. [18]. Expression plasmid of monomeric S comprise the extracellular domain of S that is C-terminally fused to the thrombin site, fibrinogen trimerization sequence, and a Strep-tag II plus a His tag cloned into a PCXSN vector. S proteins were expressed using the Expi293 Expression System (Thermo Fisher Scientific Inc., Waltham, MA, USA), according to the manufacturer’s instructions. Seven days post-transfection, the medium was clarified by centrifugation at 1200 × g, filtered, and purified with Ni–NTA Agarose (QIAGEN, Germantown, MD, USA). The purified S proteins were concentrated using Amicon Ultracell (Merck) centrifugation units with a cut-off of 50 kDa, and the buffer was changed to PBS (pH 7.4). The proteins were filtered through Cosmospin filter G with a pore size of 0.2 micron (Nacalai Tesque, Inc.) and stored at − 80 °C until use.

IgG-ELISA
The IgG-ELISA was performed as described below. Briefly, 96-well ELISA plates were coated with the predetermined optimal quantity of purified SARS-CoV-2 S protein (approximately 100 ng/well) at 4 °C overnight. Each well of the plates was then covered with 200 μL of PBS containing 3% BSA and 0.1% Tween 20 (PBST-B), followed by incubation for 1 h at 37 °C for blocking. The plates were washed three times with PBS containing 0.1% Tween 20 (PBST) and then incubated with test sera (50 μL/well), which were diluted 1:1000 with PBST-B. After a 1 h incubation period, the plates were washed three times with PBST and then were incubated with goat anti-human IgG antibody labeled with HRP (1:5000 dilution; Sigma-Aldrich, St. Louis, MO, USA). After a further 1 h incubation period, the plates were washed and 50 μL of TMB solution (SeraCare life Sciences Inc., Milford, MA, USA) was added to each well. The plates were incubated for 30 min at room temperature, 50 μL of TMB stop soln.

Neutralization assays with patient blood samples
The patient sera used in this study were collected from participants after obtaining informed consent. To examine neutralization of the human serum or whole blood samples against pseudotyped viruses, Vero cells were treated with serially diluted sera or whole blood of convalescent patients with COVID-19 or COVID-19 PCR-negative donors and then inoculated with Sfullpv, St19pv, valescent patients with COVID-19 or COVID-19 PCR-negative donors was assessed using the real-time PCR method with specific primers, which were developed at the National Institute of Infectious Diseases, Japan [17].

Blood samples
Twenty-three serum samples were collected from hospitalized patients with COVID-19 who were admitted to the University of Toyama Hospital, Toyama, Japan. In addition, nineteen serum samples were collected from COVID-19 PCR-negative donors at the University of Toyama Hospital. All of the sera were heat-inactivated at 56 °C for 30 min. The diagnosis of COVID-19 in all patients or donors was assessed using the real-time PCR method with specific primers, which were developed at the National Institute of Infectious Diseases, Japan [17].

Coomassie brilliant blue (CBB) staining and Immunoblotting
Transfection of 293 T cells occurred with pCAG-SARS-CoV-2 Sfullpv, pCAG-SARS-CoV-2 St19pv, or VSV-G. At 24 h post-transfection, the cells were collected and lysed in phosphate-buffered saline (PBS) containing 1% NP40. Then, the lysates were centrifuged to separate insoluble pellets from supernatants. The supernatants were used as samples. The Sfullpv or St19pv, which were generated as described above, were pelleted through a 20% (wt/vol) sucrose cushion at 25,000 rpm for 2 h in an SW41 rotor (Beckman Coulter, Tokyo, Japan). Then, the pellets were resuspended in PBS. Each sample that was boiled in loading buffer was subjected to 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE). According to the manufacturer’s protocol, the proteins in the gel were stained with CBB Stain One (Nacalai Tesque, Inc.). Next, the proteins in another gel were electrophoretically transferred to a methanol-activated polyvinylidene difluoride (PVDF) membrane (Millipore, Billerica, MA) and reacted with COVID-19 hospitalized patient sera (#12). Then, immune complexes were visualized with SuperSignal West Dura Extended Duration Substrate (Pierce, Rockford, IL) and detected by an LAS3000 analyzer (Fuji Film, Tokyo, Japan).

IgG-ELISA
The IgG-ELISA was performed as described below. Briefly, 96-well ELISA plates were coated with the predetermined optimal quantity of purified SARS-CoV-2 S protein (approximately 100 ng/well) at 4 °C overnight. Each well of the plates was then covered with 200 μL of PBS containing 3% BSA and 0.1% Tween 20 (PBST-B), followed by incubation for 1 h at 37 °C for blocking. The plates were washed three times with PBS containing 0.1% Tween 20 (PBST) and then incubated with test sera (50 μL/well), which were diluted 1:1000 with PBST-B. After a 1 h incubation period, the plates were washed three times with PBST and then were incubated with goat anti-human IgG antibody labeled with HRP (1:5000 dilution; Sigma-Aldrich, St. Louis, MO, USA). After a further 1 h incubation period, the plates were washed and 50 μL of TMB solution (SeraCare life Sciences Inc., Milford, MA, USA) was added to each well. The plates were incubated for 30 min at room temperature, 50 μL of TMB stop soln.
(SeraCare life Sciences) was added to each well, and the optical density at 450 nm (OD$_{450}$) was measured. The adjusted OD$_{450}$ value was calculated by subtracting the OD$_{450}$ value of the negative Ag-coated wells from that of the corresponding wells. The mean plus three standard deviations (mean ± 3SD) of the ELISA indices for the IgG-ELISAs was calculated using γ-globulin and was used as the cut-off value for the IgG-ELISAs.

Immunofluorescence assay (IFA)

For the IFA, BHK cells transfected with pCAG-SARS-CoV-2 S-full were fixed with acetone-methanol (1:1) at 4 °C for 20 min. Fixed cells were reacted with the test serum samples, which were diluted at 1:100 with PBS. After an incubation for 1 h, the cells were rinsed with PBS and incubated with goat anti-human Alexa Fluor 488 (Invitrogen). After washing with PBS, staining was observed under a fluorescence microscope.

Statistical analysis

Unpaired $t$-test with Welch's correction or two-way ANOVA was used to determine significant differences in the data using the GraphPad Prism 7 software program (GraphPad software, La Jolla, CA).

Ethics statement

All of the samples, protocols, and procedures were approved by the Research Ethics Committee at the University of Toyama for the use of human subjects (approval number: R2019167).

Results

Production and characterization of SARS-CoV-2 Sfullpv and St19pv

SARS-CoV-2 Sfullpv, St19pv, and VSVpv were generated in 293 T cells transiently expressed with full length-, truncated S proteins of SARS-CoV-2 and VSV-G, respectively, upon infection of 293 T cells with *G-VSV∆G/Luc, as previously reported [16]. To confirm the incorporation of S proteins into Sfullpv or St19pv particles, the pseudotyped viruses were purified by ultracentrifugation and analyzed using immunoblotting and the serum of COVID-19 hospitalized patient (Fig. 1a, right panel). The S1 and S2 proteins in Sfullpv or St19pv and Sfull- or St19-expressing cell lysates were detected but not in VSV that lacked an envelope protein (ΔGpv) or mock cells (Ctrl). The VSV structural proteins, nucleoprotein (N), and matrix protein (M) were also detected in Sfullpv, St19pv, and ΔGpv by CBB staining (Fig. 1a, left panel). Overall, the amount of St19 proteins incorporated was higher than that of Sfull proteins, although the amount of structural proteins of VSV was almost the same level among all the virions.

These results indicate that the incorporation of truncated S proteins into VSV particles was more efficient than the full-length S protein.

Next, ΔGpv, Sfullpv, St19pv, and VSVpv were inoculated into the indicated cell lines to examine the infectivity of pseudotyped viruses to various mammalian cell lines (Fig. 1b). Among the tested cell lines, Hu7, 293 T, Vero, and BHK cells were susceptible to Sfullpv and St19pv infection. NIH3T3 cells were less susceptible to infection by both Sfullpv and St19pv, while CHO cells showed no susceptibility. Notably, the infectivity of St19pv was higher than that of Sfullpv in Vero cells.

To determine the specificity of infection of Sfullpv and St19pv, a neutralization assay of the pseudotyped viruses was performed using sera of two hospitalized COVID-19 patients. The infectivity of Sfullpv and St19pv, but not that of VSVpv in Vero cells, were clearly inhibited by sera of the patients in a dose-dependent manner (Fig. 2).
These data indicated that Sfullpv and St19pv infection exhibited an S protein-mediated entry.

Neutralization test for COVID-19 hospitalized patients or COVID-19 PCR-negative donors by pseudotyped viruses
To examine the neutralization of COVID-19 hospitalized patients or COVID-19 PCR-negative donors against St19pv, Vero cells with each serum were infected with St19pv and VSVpv. Neutralization of St19pv was observed based on the sixteen sera of COVID-19 hospitalized patients at a rate of more than 99% (Fig. 3a). Sera, which did not show the neutralization of St19pv, were derived from COVID-19 hospitalized patients who were hospitalized for a short period before antibody production (such as within 3 days after onset). No neutralization was observed in the VSVpv infection by any of the sera of COVID-19 hospitalized patients and in both St19pv and VSVpv infection by any of the sera of COVID-19 PCR-negative donors (Fig. 3a, b). The dot plot graph shows a classification of each pseudotyped virus from Fig. 3a, b graphs (Fig. 3c). Due to the presence of convalescent and non-convalescent patient sera, the degree of neutralization activity of St19pv by COVID-19 hospitalized patient sera was variable.

IgG-ELISA or IFA for COVID-19 hospitalized patients or COVID-19 PCR-negative donors
To examine the correlation of the antibody titers using CRNT compared to those determined by the IgG-ELISA or IFA, the IgG-ELISA or IFA was also performed using COVID-19 hospitalized patients or COVID-19 PCR-negative donors. Although the correlation between OD value of ELISA and neutralizing activity of St19pv exhibited in almost all of the patient sera, some of the sera (No. 8, 18, 20, 21, 22, 23) were not correlated (Figs. 3 and 4). The correlation between fluorescence intensity of IFA and neutralizing activity of St19pv also exhibited in almost all of the patient sera, but in No.13 serum, the fluorescence intensity of IFA was negative even though the neutralizing activity of St19pv was observed in the CRNT (Fig. 3 and Table 1). COVID-19 PCR-negative donor sera that demonstrated no neutralizing activity in the CRNT were also negative by both ELISA and IFA (Figs. 3b, 4b, and Table 1).

Comparison of patient sera and whole blood in the neutralization of pseudotyped viruses
To investigate an antibody survey against COVID-19 in a large number of people, we verified whether even a small amount of whole blood could be evaluated by the CRNT. Therefore, we compared the neutralizing effect of pseudotyped viruses between the sera and whole blood of COVID-19 hospitalized patients (Fig. 5). After centrifugation of whole blood, hematopoietic cells, including red blood cells, may be removed. As a result, the neutralization of St19pv infection with 1:200 diluted sera or whole blood was almost the same (Fig. 5). Furthermore, the values indicating 50% inhibitory concentration of infection (IC50) were also almost the same in both sera and whole blood (Table 2). These results indicated that even a small amount of whole blood can sufficiently evaluated the presence of neutralizing antibody in the CRNT.

Discussion
A rapid, safe, and highly sensitive CRNT system using VSV-based pseudotyped viruses with SARS-CoV-2 S or truncated S proteins was developed. Because this system...
Fig. 3 Neutralization of St19pv and VSVpv infections through sera from hospitalized patients with COVID-19 or a COVID-19 PCR-negative donor. The pseudotyped viruses were preincubated with a 100-fold dilution of sera from 23 hospitalized COVID-19 patients (a) or 19 COVID-19 PCR-negative donors (b). Thereafter, Vero cells were infected with pseudotyped viruses. Infectivities of pseudotyped viruses were determined by measuring luciferase activities 24 h post-infection. The results are from three independent assays with error bars representing standard deviations. c A summary of the results of (a) and (b) divided by pseudotyped viruses are represented by dot plot analyses. The significance of any differences in the means was determined using the Student’s t test. ****P < 0.0001
utilizes replication and translation of VSV, neutralization against pseudotyped virus infection can be determined within 12–16 h. Another pseudotyped viral system that uses retroviral or lentiviral vectors takes approximately 48 h to obtain results. Therefore, the VSV-based pseudotyped viral system is considered more useful. In addition, since measurement of luciferase activity is a quantitative method, it is not necessary to count GFP-positive cells. Therefore, this CRNT system permits a simple and objective evaluation for the neutralization.

For many viral species, CRNT systems were developed using VSV-pseudotyped viruses with their own envelope proteins [16, 19–21]. In SARS-CoV-2, researchers recently demonstrated the construction of pseudotyped viruses and evaluation of the presence of neutralizing antibodies [8–12, 22].

In this study, we prepared a pseudotyped virus that possesses a truncated SARS-CoV-2 S protein, which showed higher infectivity. Furthermore, the neutralizing activity of the test sera and whole blood against the pseudotyped virus was quantitatively detected in a convalescent patient with COVID-19, while the donor sera of the COVID-19 PCR-negative patient showed a negative reaction. In the CRNT of St19pv, the infectivity of St19pv was reduced by 99% or more by the convalescent phase patient sera. This demonstrated that the convalescent...
phase patient sera of COVID-19 exhibited a high neutralizing antibody activity. The results determined by the CRNT also correlated with those determined by the ELISA or IFA. Antibodies against the S protein of SARS-CoV-2 in COVID-19 convalescent patient sera were capable of neutralizing the viral infection.

If using whole blood in the CRNT becomes possible, the work of separating serum will no longer be necessary. The CRNT can be performed with an extremely small amount of blood sample (only a few microliters). Therefore, when we confirmed that the CRNT with whole blood of the convalescent phase patient of COVID-19 was possible, a high neutralizing activity by the CRNT should be observed. The results showed that there was only a weak correlation in the ELISA and IFA, suggesting that there are antibodies that do not react with the S protein. We will need to study this controversial phenomenon in detail. In the future, the natural infection of SARS-CoV-2 is expected to increase the antibody prevalence in healthy individuals. It will be possible to conduct a large-scale investigation using the CRNT as to how many people have neutralizing antibodies. It may also help determine the antibody prevalence of vaccinated individuals after being vaccinated with COVID-19.

Conclusions

The neutralizing antibody measurement system using pseudotyped viruses for SARS-CoV-2 is an effective tool for evaluating the presence or duration of the neutralizing antibody in convalescent patients and to screen for those who present with the neutralizing antibody among suspected populations. In addition, this CRNT system does not require the use of infectious

### Table 1 Intensity of IF positive cells expressing SARS-CoV-2 S protein

| Hospitalized COVID-19 patient sera | COVID-19 PCR-negative donor sera |
|-----------------------------------|----------------------------------|
| No | IF-Intensity | No | IF-Intensity |
|----|--------------|----|--------------|
| 1  | ++ +         | 1  | -            |
| 2  | ++ +         | 2  | -            |
| 3  | ++           | 3  | -            |
| 4  | ++ +         | 4  | -            |
| 5  | ++ +         | 5  | -            |
| 6  | ++ +         | 6  | -            |
| 7  | ++ +         | 7  | -            |
| 8  | ++ +         | 8  | -            |
| 9  | ++ +         | 9  | -            |
| 10 | ++           | 10 | -            |
| 11 | ++ +         | 11 | -            |
| 12 | ++ +         | 12 | -            |
| 13 | -            | 13 | -            |
| 14 | -            | 14 | -            |
| 15 | -            | 15 | -            |
| 16 | -            | 16 | -            |
| 17 | -            | 17 | -            |
| 18 | +            | 18 | -            |
| 19 | -            | 19 | -            |
| 20 | +            |    |              |
| 21 | ++           |    |              |
| 22 | ++           |    |              |
| 23 | ++           |    |              |

SARS-CoV-2 S protein-expressing BHK cells were reacted with the hospitalized COVID-19 patient sera or COVID-19 PCR-negative donor sera. IF-Intensity was evaluated by observation under a fluorescence microscope. IF-Intensity was stronger in the order of ++ + > ++ > ++ > + > + > -

### Fig. 5

Effects on the neutralization of St19pv infection by serum or whole blood from COVID-19 hospitalized patients. The pseudotyped viruses were preincubated with two hundred dilutions of serum or whole blood from seven different COVID-19 hospitalized patients (patients #6, #7, #12, #20, #21, #22, and #23) with culture media. Thereafter, Vero cells were infected with pseudotyped viruses. Infectivities of pseudotyped viruses were determined by measuring luciferase activities 24 h post-infection. The results are from three independent assays with error bars representing standard deviations. 

![Relative % of infectivity](image-url)
**Table 2** The 50% inhibitory concentration of infection (IC₅₀) of St19pv and VSVpv by serum or whole blood from COVID-19 hospitalized patients

| No | Serum (IC₅₀) | VSVpv |
|----|-------------|-------|
|    | × 1600      | × 25  |
| #6 | > × 6400    | × 50  |
| #7 | × 1600      | × 25  |
| #12| × 3200      | < × 25|
| #20| × 400       | < × 25|
| #21| × 200       | < × 25|
| #22| × 400       | < × 25|
| #23| × 100       |       |

Whole blood (IC₅₀)

| No | Serum (IC₅₀) | VSVpv |
|----|-------------|-------|
|    | × 1600      | × 100 |
| #6 | > × 6400    | × 100 |
| #7 | × 1600      | × 100 |
| #12| × 1600      | × 100 |
| #20| × 800       | × 100 |
| #21| × 400       | × 100 |
| #22| × 100       |       |
| #23| × 100       |       |

The pseudotyped viruses, St19pv or VSVpv, were preincubated with serial dilutions (× 25, > × 50, × 200, > × 400, × 800, > × 1600, × 3200, > × 6400) of serum or whole blood from seven different COVID-19 hospitalized patients (patients #6, #7, #12, #20, #21, #22, and #23) with culture media. Thereafter, Vero cells were infected with pseudotyped viruses. Infectivities of pseudotyped viruses were determined by measuring luciferase activities 24 h post-infection. IC₅₀ value was calculated and determined as shown in the dilution range. The results are from three independent assays with error bars representing standard deviations.

viruses to measure neutralizing antibodies. Therefore, once the pseudotyped virus system is established, it can be made available at many laboratories without BSL-3 facilities. Furthermore, because of the measuring system by chemiluminescence, the results can be obtained safely and quickly. Finally, the CRNT using whole blood is a simpler and safer method because it can be measured with only a very small amount of blood from an eligible person.

**Abbreviations**

COVID-19: Coronavirus Disease 2019; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; CRNT: Chemiluminescence reduction neutralization test; VSV: Vesicular stomatitis virus; IFA: Immunofluorescence assay; EDTA: Ethylenediaminetetraacetic acid; PVDF: Polyvinylidene difluoride; SDS-PAGE: Sodium dodecyl sulfate–polyacrylamide gel electrophoresis.

**Acknowledgements**

We gratefully acknowledge Ms. Kaoru Hounoki and Yoriko Ito for technical and secretarial assistance.

**Authors’ contributions**

HT, YYa, and YM designed the study. HT, MK, LT, YYo, KS, TS, TO, HK, and SF performed the experiments. SF, KS, and TS provided materials. HK, AU, YM, YF, IS collected the samples and contributed to completion of the study. HT, MK, KS, TS, MS, and YM wrote and edited the manuscript. All authors reviewed the results and approved the final manuscript version.

**Funding**

This work was supported in part by Grants-in-Aid from the Japan Agency for Medical Research and Development (AMED) to Y.M. (JP20fhe0622035) and T.S. (JP19kk0108110).

**Availability of data and materials**

The datasets analyzed during the current study are available from the corresponding author on reasonable request.

**Ethics approval and consent to participate**

All of the samples, protocols, and procedures were approved by the Research Ethics Committee at the University of Toyama for the use of human subjects (Approval Number: R2019167).

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare no conflicts of interest in association with the present study.

**Author details**

1 Department of Microbiology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan. 2 Department of Virology, Toyama Institute of Health, Toyama, Japan. 3 Department of Immunology, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan. 4 Department of Virology I, National Institute of Infectious Diseases, Tokyo, Japan. 5 Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan. 6 Department of Clinical Infectious Diseases, Faculty of Medicine, Academic Assembly, University of Toyama, Toyama, Japan.

**Received: 1 October 2020 Accepted: 6 January 2021**

**Published online: 12 January 2021**

**References**

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
2. Musa A, Pendi K, Hashemi A, Warbasse E, Kouyoumjian S, Yousif J, Blodget E, Stevens S, Aly B, Baron DA. Remdesivir for the treatment of COVID-19: a systematic review of the literature. West J Emerg Med. 2020;21:737–41.
3. Tu H, Tu S, Gao S, Shao A, Sheng J. Current epidemiological and clinical features of COVID-19: a global perspective from China. J Infect. 2020;81:1–9.
4. Jin Y, Yang H, Ji W, Wu W, Wu C, Zhang S, Zhang W, Duan G. Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses. 2020;12:372.
5. Li Q, Liu Q, Huang W, Li X, Wang Y. Current status on the development of pseudoviruses for enveloped viruses. Rev Med Virol. 2018;28:e1963.
6. Joglekar AV, Sandoval S. Pseudotyped lentiviral vectors: one vector. Many guises Hume Gene Ther Methods. 2017;28:291–301.
7. Whitt MA. Generation of HSV pseudotypes using recombinant deltaAG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines. J Virol Methods. 2010;169:365–74.
8. Nie J, Li Q, Wu J, Zhao C, Hao H, Liu H, Zhang L, Nie L, Qin H, Wang M, et al. Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2. Emerg Microbes Infect. 2020;9:680–6.
9. Case JB, Rothlauf PW, Chen RE, Liu Z, Zhao H, Kim AS, Bloyet LM, Zeng Q, Tahan S, Droit L, et al. Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2. Cell Host Microbe. 2020;28:475–85S-e475.
10. Zettl F, Meister TL, Vollmer T, Fischer B, Steinmann J, Krawczyk A, V’Kovski P, Todt D, Steinmann E, Paender S, Zimmer G. Rapid quantification of SARS-CoV-2-neutralizing antibodies using propagation-defective vesicular stomatitis virus pseudotypes. Vaccines (Basel). 2020;8:386.
11. Tan CW, Chia WN, Qin X, Liu P, Chen MI, Tu C, Hu Z, Chen VC, Young BE, Sia WR, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein–protein interaction. Nat Biotechnol. 2020;38:1073–8.
12. Almahboub SA, Algaissi A, Alfaleh MA, ELAssouli MZ, Hashem AM. Evaluation of neutralizing antibodies against highly pathogenic coronaviruses: a detailed protocol for a rapid evaluation of neutralizing antibodies using vesicular stomatitis virus pseudovirus-based assay. Front Microbiol. 2020;2020:11.

13. Sajjo M, Qing T, Niikura M, Maeda A, Ikegami T, Prehaud C, Kurane I, Morikawa S. Recombinant nucleoprotein-based enzyme-linked immunosorbent assay for detection of immunoglobulin G antibodies to Crimean-Congo hemorrhagic fever virus. J Gen Virol. 2002;40:1587–91.

14. Fukushi S, Mizutani T, Sajjo M, Matsuyama S, Miyajima N, Taguchi F, Itamura S, Kurane I, Morikawa S. Vesicular stomatitis virus pseudotyped with severe acute respiratory syndrome coronavirus spike protein. J Gen Virol. 2005;86:2269–74.

15. Kawase M, Shirato K, Matsuyama S, Taguchi F. Protease-mediated entry via the endosome of human coronavirus 229E. J Virol. 2009;83:712–21.

16. Tani H, Shiokawa M, Kaname Y, Kambara H, Mori Y, Abe T, Morishita K, Matsuura Y. Involvement of ceramide in the propagation of Japanese encephalitis virus. J Virol. 2010;84:2798–807.

17. Shirato K, Nao N, Katao H, Takayama I, Saito S, Kato F, Kato H, Sakata M, Nakatsu Y, Mori Y, et al. Development of genetic diagnostic methods for detection for novel coronavirus 2019(nCoV-2019) in Japan. Jpn J Infect Dis 2020; 73.

18. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THG, Chromikova V, McMahon M, Chu HY, Tortorici MA, Veesler D, et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat Med. 2020;26:1033–6.

19. Sakata M, Tani H, Anraku M, Kataoka M, Nagata N, Seki F, Tahara M, Otsubo N, Okamoto K, Takeda M, Mori Y. Analysis of VSV pseudotype virus infection mediated by rubella virus envelope proteins. Sci Rep. 2017;7:11607.

20. Tani H, Iha K, Shimojima M, Fukushi S, Taniguchi S, Yoshikawa T, Kawaoka Y, Nakasone N, Ninomiya H, Sajjo M, Morikawa S. Analysis of Lujo virus cell entry using pseudotype vesicular stomatitis virus. J Virol. 2014;88:7317–30.

21. Tani H, Shimojima M, Fukushi S, Yoshikawa T, Fukuma A, Taniguchi S, Morikawa S, Sajjo M. Characterization of glycoprotein-mediated entry of severe fever with thrombocytopenia syndrome virus. J Virol. 2016;90:5292–301.

22. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veesler D, Murphy M, et al. Protocol and reagents for pseudotyping lentiviral particles with SARS-CoV-2 spike protein for neutralization assays. Viruses. 2020;12:513.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.